Fig. 1From: Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancerCumulative exposure to bevacizumab at 60, 120, 182, 365 and 730 days after baseline. One unit on the x-axis is equivalent to the dose of bevacizumab received during one cure (5 mg/kg)Back to article page